Three-Year Survival Results From An Ongoing Phase 2 Study Of Brentuximab Vedotin In Patients With Relapsed Or Refractory Systemic Anaplastic Large Cell Lymphoma
作者:
Ramchandren, Radhakrishnan
Ramchandren, Radhakrishnan
D O I:
10.1182/blood.V122.21.1809.1809